The biotechnology industry in the U.S. is one of the industries that have recorded tremendous advances. Biotech executives like Clay Siegall believe that technology has influenced these advances. According to Siegall, cancer therapies such as Celgene’s lenalidomide and Roche/Genentech’s trastuzumab have been effective in treating different types of cancer. He also believes that over the past years, significant advances have been made in the development of HIV therapies. In an article posted in his blog, Siegall gave an example of efavirenz, tenofovir, and emtricitabine that help in boosting the immunity of HIV patients. Gilead Sciences developed these drugs.
Biotechnological research works have also led to the development of improved flu vaccines. They have also influenced the development of hepatitis C therapies. Vertex Pharmaceuticals recently made news after developing telaprevir as a medication for hepatitis C. Dendreon, a pharmaceutical company, also developed sipuleucel-T as a tumor vaccine.
Clay Siegall’s Professional and Academic Background
Clay Siegall is a biotech executive who is celebrated for his leadership role in Seattle Genetics, a company he co-founded in 1998. Besides serving as the company’s CEO, Siegall also seats at the executive directors’ board. He has led Seattle Genetics in the development of outstanding clinical and preclinical products. The company is the pioneer of the antibody-drug conjugate (ADC) technology. This technology is used to develop drugs for treating cancer and autoimmune diseases. As CEO, Siegall has facilitated capital-raising ventures for the company through private and public financings. Seattle Genetics has also collaborated with leading biotech companies such as MedImmune, Genentech, and Bayer. Through such partnerships, Seattle Genetics has generated over $800 million.
Siegall earned a bachelor’s degree in Zoology after completing his undergraduate studies at the University of Maryland. He also obtained a doctorate in Genetics after graduating from the George Washington University. He has worked as an executive for the National Cancer Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. His executive board membership roles are beneficial to the Fred Hutchinson Cancer Research Business Alliance and Alder Biopharmaceuticals. He was also named as a member of the executive board of the Washington Biotechnology and Biomedical Association (WBBA).